Neo-RT: 治療順序の変更 (手術前に放射線療法を開始し、続いてホルモン療法を開始) が実行可能かどうかを調査する研究 (Neo-RT)
Neo-RT:乳がんのネオアジュバントホルモン治療を受けている患者における術前乳房強度変調放射線療法 - 実現可能性研究。
Four in 10 women diagnosed with breast cancer undergo mastectomy with or without breast reconstruction and less than half are satisfied with how they look unclothed. Breast conservation (removing the area with the lump only) can offer less extensive surgery and improved breast appearance, which can therefore increase well-being.
Intensity-modulated radiotherapy (IMRT) closely shapes the radiation beam to the cancer and is currently given after breast surgery. A new combination of IMRT followed by hormone treatment given before surgery, may increase the possibility of breast conservation.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Cambridgeshire
-
Cambridge、Cambridgeshire、イギリス、CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Women with invasive breast cancer for planned treatment with neo-adjuvant endocrine therapy, where radiotherapy may make breast conserving surgery easier.
説明
Inclusion Criteria:
- Written informed consent to participate
- Female
- Aged 18 years and older
- ECOG performance status 0-2
- Histology confirmed invasive breast cancer
- ER positive (Allred score 6-8)
- HER2 negative
- Palpable size ≥20mm
- Grade I-II (or grade III if considered not suitable for neo-adjuvant chemotherapy)
- Considered that radiotherapy will make breast conserving surgery easier
- No evidence of non-breast malignancy if treated with curative intent unless the patient has been disease free ≥5 years
- Unifocal or multifocal disease, i.e. tumour in the same quadrant and breast conserving surgery still feasible
Exclusion Criteria:
- Contraindications to breast radiotherapy or neo-adjuvant endocrine therapy
- Bilateral breast cancer
- Metastatic cancer
- Multicentric disease
- Concomitant medical/psychiatric problems preventing completion of study treatment or follow-up
- Pregnancy
- Breast feeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The proportion of patients successfully completing neo-adjuvant IMRT and endocrine treatment followed by beast surgery, as per study protocol.
時間枠:6 months
|
Successful completion of IMRT is defined as:
Successful completion of endocrine treatment is defined as:
Successful surgery is defined as:
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acute radiotherapy toxicity following IMRT, assessed by CTCAE v4.03
時間枠:3 weeks
|
Acute radiotherapy toxicity following IMRT, assessed by CTCAE v4.03 |
3 weeks
|
|
Mastectomy rate
時間枠:6 months
|
Analysis will be descriptive, and in accordance to the statistical analysis plan. |
6 months
|
|
Peri/post operative complications
時間枠:9 months
|
Including:
|
9 months
|
|
Volume of residual tumour and response to treatment
時間枠:6 months
|
There will be a central review (2 readers) of all primary surgery histopathology reports for the secondary endpoint of pathological complete response (pCR). The histopathology slides from the surgical resection will be requested for central assessment of residual disease for all cases where there has not been a pCR. The variables that will be recorded include residual invasive tumour size in two dimensions, residual invasive tumour cellularity, number of lymph node metastases and size of the largest metastasis. A representative tumour tissue block will be selected and requested from the laboratory. Sections from the block will be taken for staining with ER and Ki67 to allow calculation of the histological assessment of residual tumour burden, and cores taken as per the protocol. |
6 months
|
|
Late normal tissue toxicity, as assessed by: 1) clinicians
時間枠:Annually for 5 years
|
Clinician - post-radiotherapy questionnaire (with permission from IMPORT Trial Management Group and Dr Penny Hopwood) |
Annually for 5 years
|
|
Late normal tissue toxicity, as assessed by: 2) Patient Reported Outcome Measurements (PROMs)
時間枠:Annually for 5 years
|
Patient Reported Outcome Measure - Validated Breast-Q questionnaire |
Annually for 5 years
|
|
Late normal tissue toxicity, as assessed by: 2) Patient Reported Outcome Measurements (PROMs)
時間枠:Annually for 5 years
|
Patient Reported Outcome Measure - EORTC IL1 Modified BRECON23 PROM questionnaire. |
Annually for 5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory research will be carried out to identify possible molecular and radiological biomarkers of response
時間枠:6 months post last patient recruited
|
Exploratory investigation of potential biomarkers include:
Immune response (TILs) Tumour proliferation (Ki67, Geminin) DNA damage response and cell cycle checkpoint activation (including 53BP1, RAD51, ATM1, BRCA1, p53, p21 and p-chk-1) Tumour microenvironment (hypoxia) - Multiplexed single cell proteomics of both cellular suspensions (including whole blood) and intact tissues, to investigate the immune response and other novel markers Since the identification of new biomarkers correlating with disease activity and the efficacy or safety of treatment is rapidly evolving, the definitive list of biomarkers remains to be determined. However they will be detailed in an appropriate analysis plan prior to undertaking any sample analysis. |
6 months post last patient recruited
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Charlotte E Coles, MB ChB, MRCP, FRCR, PhD、University of Cambridge
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Neo-RT
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。